Document is current
Any future updates will be listed below
-
Authors
Tolosa, Pablo
García-Fructuoso, Isabel
Pascual, Tomás
Martínez-Sáez, Olga
Cejalvo, Juan Miguel
Servitja, Sonia
Fernández Abad, María
Benitez Fuentes, Javier David
Brasó-Maristany, Fara
Sanfeliu, Ester
Lema, Laura
Ruano, Yolanda
Parrilla, Lucía
Roncero, Ana María
Cobos, María Ángeles
Díaz, Irene
Centelles López, Karla Alicia
Sánchez-Bayona, Rodrigo
Alva, Manuel
Madariaga, Ainhoa
Villacampa, Guillermo
Salvador, Fernando
Sánchez-Belmonte, Agustín
Malumbres, Marcos
Prat, Aleix
Ciruelos, Eva
-
Funding
Funding for this research was provided by:
"Proyectos Líneas Estratégicas Colaboración" funded by the Ministerio de Inovación y Ciencias and the "Unión Europea Next Generation" (PLEC2021-007892)
Instituto de Salud Carlos III (DTS21/00111)
Instituto de Salud Carlos III (PI 18/01408)
the "Proyectos Líneas Estratégicas Colaboración" funded by the Ministerio de Inovación y Ciencias and the "Unión Europea Next Generation" (PLEC2021-007892)
Fundación FERO
Funding from the first edition of the mama's chukker charity polo match held in Madrid in 2023
- License Information
-
More Information
Article History
Received: 4 November 2025
Accepted: 17 February 2026
First Online: 28 February 2026
Declarations
:
: P.T. reports advisory and consulting fees from AstraZeneca, Daiichi Sankyo, Adamed, Novartis, Pfizer, Lilly, Esteve, Gilead, Roche, and Reveal Genomics. I.G-F. reports invited speaker fees from Novartis, Daiichi Sankyo, and Eisai; advisory/consulting fees from Novartis; and travel expenses from Novartis, Gilead, and Lilly. T.P. reports advisory and consulting fees or speaker honoraria from Novartis, AstraZeneca, Lilly, Pfizer, Veracyte, Gilead, and Roche, and support for attending meetings and/or travel from Gilead. O.M-S. reports advisory/consulting fees from Reveal Genomics, Roche, and AstraZeneca; lecture fees from Daiichi Sankyo, Novartis, Pfizer, and Eisai; and travel expenses from Gilead and Novartis. E.S. reports participation in advisory boards and as a speaker for AstraZeneca and Sysmex, and consultancy for Reveal Genomics Inc. F.B-M. reports patents filed (PCT/EP2022/086493, PCT/EP2023/060810, EP23382703, and EP23383369) and part-time employment by Reveal Genomics. R.S-B. reports advisory/consulting/speaker fees from Roche, AstraZeneca, Novartis, Lilly, Daiichi Sankyo, Pfizer, Eisai, GlaxoSmithKline, Reveal Genomics, and Gilead; and travel expenses from Pfizer, AstraZeneca, Gilead, Novartis, and Roche. A.M. reports honoraria from AstraZeneca, Clovis, GSK, PharmaMar, Immunogen, and Pharma&. F.S. has been employed by AstraZeneca since June 2024; however, involvement in this study predates this employment, and AstraZeneca had no involvement in the study. M.M. reports advisory/consulting/speaker fees or grant support from AstraZeneca, PharmEnable, PharmaMar, and Circle Pharma. A.P. reports advisory and consulting fees from AstraZeneca, Roche, Pfizer, Novartis, Daiichi Sankyo, Ona Therapeutics, and Peptomyc; lecture fees from AstraZeneca, Roche, Novartis, and Daiichi Sankyo; institutional financial interests from AstraZeneca, Novartis, Roche, and Daiichi Sankyo; stockholder and employee of Reveal Genomics; and patents filed (PCT/EP2016/080056, PCT/EP2022/086493, PCT/EP2023/060810, EP23382703, and EP23383369). E.C. reports advisory/consulting/speaker fees from Roche, AstraZeneca, Novartis, Lilly, Daiichi Sankyo, Pfizer, and Gilead; and travel expenses from Pfizer, AstraZeneca, MSD, Novartis, and Roche. All remaining authors have declared no conflicts of interest.
